Profile

Bright Angel Therapeutics (BAT) is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections. The company is powered by Schrödinger’s computational drug discovery platform in addition to proprietary technologies which the company has developed to enable design and development of fungal-selective inhibitors. BAT is currently working on two programs targeting invasive fungal infections (see pipeline). The company is headquartered in Toronto, Ontario, Canada.

Bright Angel Therapeutics logo

Website

brightangeltherapeutics.com

Contact


Event details

Date: November 6 - 8, 2023

Event contact

Patrick Barry
Area Director
Europe: Automotive and Life Sciences

Participants

21 in total